MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® are proprietary therapeutic proteins based on single-domain antibody fragments, with the benefits of conventional antibodies but at 1/10th the size. MoonLake has licensed Merck KGaA’s phase 3-ready drug sonelokimab (M1095) […]

View post to subscribe to site newsletter.

ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham. Chronic respiratory illness is associated with lung dysbiosis (abnormal lung microbiome) […]

View post to subscribe to site newsletter.

Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are resistant to or recovered from disease. Alchemab’s approach was developed with support from scientific founders at Oxford University, Johns Hopkins University and Mount Sinai Hospital. The company’s approach starts by […]

View post to subscribe to site newsletter.